These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33191310)

  • 1. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.
    Banerjee R; Ali RAR; Wei SC; Adsul S
    Gut Liver; 2020 Nov; 14(6):685-698. PubMed ID: 33191310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of vedolizumab in a patient with Crohn's disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report.
    Sugiyama Y; Ueno N; Tachibana S; Kobayashi Y; Murakami Y; Sasaki T; Sakatani A; Takahashi K; Ando K; Kashima S; Moriichi K; Tanabe H; Okumura T; Fujiya M
    Medicine (Baltimore); 2023 Jul; 102(28):e34331. PubMed ID: 37443475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):30-36. PubMed ID: 29024102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.
    Lee JY; Oh K; Hong HS; Kim K; Hong SW; Park JH; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Lee HS; Jo KW; Park SH
    BMC Gastroenterol; 2021 Oct; 21(1):390. PubMed ID: 34670529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
    Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
    Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America.
    Fortes FML; Sorte NB; Mariano VD; Andrade LD; Oliveira FA; Santos MC; Dos Santos CIN; Passos CA; Pacheco MP; Surlo VC; de Almeida NP; Fontes JA; Pimentel AM; Rocha R; Santana GO
    World J Gastroenterol; 2020 Nov; 26(44):6993-7004. PubMed ID: 33311945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease].
    Jin BC; Moon HJ; Kim SW
    Korean J Gastroenterol; 2022 Aug; 80(2):72-76. PubMed ID: 36004634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy.
    Kim J; Im JP; Yim JJ; Lee CK; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Korean J Gastroenterol; 2020 Jan; 75(1):29-38. PubMed ID: 31986571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
    Na SY; Kim YS
    Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists.
    Hou JK; Kramer JR; Richardson P; Sansgiry S; El-Serag HB
    Inflamm Bowel Dis; 2017 Feb; 23(2):254-260. PubMed ID: 27997433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.